» Articles » PMID: 34453345

Occurrence of Symptoms in Different Stages of Duchenne Muscular Dystrophy and Their Impact on Social Participation

Overview
Journal Muscle Nerve
Date 2021 Aug 28
PMID 34453345
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction/aims: As life expectancy improves for patients with Duchenne muscular dystrophy (DMD), new symptoms are likely to arise. This aims of this study are: (1) to explore the prevalence of a broad variety of symptoms in the various stages of DMD (with and without steroid use); (2) to explore the prevalence of common secondary diagnoses; and (3) to evaluate the social participation level of patients with DMD older than 16 y of age; and to explore correlations between social participation and symptoms.

Methods: A cross-sectional self-report questionnaire, including questions on functional level and health status, as well as a standardized participation scale was distributed among Dutch patients with DMD.

Results: Eighty-four male patients with a mean age of 22.0 (SD = 10.0) y were enrolled. The most prevalent and limiting symptoms were difficulty coughing (58%), coldness of hands (57%), contractures (51%), stiffness (49%), fatigue (40%), myalgia (38%), and low speech volume (33%). Prevalent secondary diagnoses included cardiac disease (14%), neurobehavioral diagnosis (13%), low blood pressure (13%), and arthrosis (5%). Social participation correlated negatively with coldness of hands (r = - .29; P < .03), decreased intelligibility (r = - .40; P < .003), and chewing problems (r = - .33; P < .02).

Discussion: The prevalence of a broad spectrum of symptoms and secondary diagnoses is high in patients with DMD, and some of these symptoms are correlated with social participation. Growing awareness of new symptoms and secondary diagnoses among patients, caregivers, and professionals can enhance their recognition, possibly facilitating prevention and early treatment.

Citing Articles

The Dutch Dystrophinopathy Database: A National Registry with Standardized Patient and Clinician Reported Real-World Data.

van de Velde N, Krom Y, Bongers J, Hoek R, Ikelaar N, van der Holst M J Neuromuscul Dis. 2024; 11(5):1095-1109.

PMID: 39031379 PMC: 11380288. DOI: 10.3233/JND-240061.


Detecting early signs in Duchenne muscular dystrophy: comprehensive review and diagnostic implications.

Mercuri E, Pane M, Cicala G, Brogna C, Ciafaloni E Front Pediatr. 2023; 11:1276144.

PMID: 38027286 PMC: 10667703. DOI: 10.3389/fped.2023.1276144.


Palliation, end of life care and ventilation withdrawal in neuromuscular disorders.

Elverson J, Evans H, Dewhurst F Chron Respir Dis. 2023; 20:14799731231175911.

PMID: 37199317 PMC: 10201157. DOI: 10.1177/14799731231175911.


Identification of Novel Gene Regulatory Networks for Dystrophin Protein in Vascular Smooth Muscle Cells by Single-Nuclear Transcriptome Analysis.

Shen Y, Kim I, Tang Y Cells. 2023; 12(6).

PMID: 36980233 PMC: 10047041. DOI: 10.3390/cells12060892.


Bone Quality in Patients with a Congenital Myopathy: A Scoping Review.

Bouman K, Dittrich A, Groothuis J, van Engelen B, Janssen M, Voermans N J Neuromuscul Dis. 2022; 10(1):1-13.

PMID: 36314217 PMC: 9881028. DOI: 10.3233/JND-221543.


References
1.
Andrews J, Wahl R . Duchenne and Becker muscular dystrophy in adolescents: current perspectives. Adolesc Health Med Ther. 2018; 9:53-63. PMC: 5858539. DOI: 10.2147/AHMT.S125739. View

2.
Bushby K, Finkel R, Birnkrant D, Case L, Clemens P, Cripe L . Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2009; 9(1):77-93. DOI: 10.1016/S1474-4422(09)70271-6. View

3.
Lindsay S, McAdam L, Mahendiran T . Enablers and barriers of men with Duchenne muscular dystrophy transitioning from an adult clinic within a pediatric hospital. Disabil Health J. 2016; 10(1):73-79. DOI: 10.1016/j.dhjo.2016.10.002. View

4.
Post M, van der Zee C, Hennink J, Schafrat C, Visser-Meily J, van Berlekom S . Validity of the utrecht scale for evaluation of rehabilitation-participation. Disabil Rehabil. 2011; 34(6):478-85. DOI: 10.3109/09638288.2011.608148. View

5.
Joseph S, Wang C, Bushby K, Guglieri M, Horrocks I, Straub V . Fractures and Linear Growth in a Nationwide Cohort of Boys With Duchenne Muscular Dystrophy With and Without Glucocorticoid Treatment: Results From the UK NorthStar Database. JAMA Neurol. 2019; 76(6):701-709. PMC: 6563545. DOI: 10.1001/jamaneurol.2019.0242. View